Tag: Pamlectabart tismanitin

August 2026 was a busy month for the antibody-drug conjugate (ADC) field, with activity spanning the full arc of development. Highlights included early discovery partnerships, manufacturing alliances, a practice-changing phase 3 readout in lung cancer, and the first dosing of a novel Treg-depleting ADC.

Amanitin-Based ADCs: Transforming Mushroom Toxin into Precision Oncology